Axim Biotechnologies, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OID
Catalina Valencia, President and Director of AXIM Biotechnologies, reports the acquisition of 1,086,216 shares of common stock on January 30, 2024.
OID
John W. Huemoeller II, CEO of Axim Biotechnologies, acquired convertible notes that can be converted into shares of the company's common stock.
OID
Catalina Valencia, a director and 10% owner of Axim Biotechnologies, acquired a convertible note worth $156,750, which can be converted into 7,837,500 shares of common stock.
OID
Blake Schroeder, a director at AXIM Biotechnologies, acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of common stock.
OID
Robert Cunningham, a director of Axim Biotechnologies, acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of common stock at $0.01 per share.
OID
Director Timothy R. Scott acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of AXIM Biotechnologies common stock at $0.01 per share.
OID
Peter O'Rourke, a director of AXIM Biotechnologies, acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of common stock.
OID
Robert Malasek, CFO of AXIM Biotechnologies, acquired a convertible note worth $53,500, which can be converted into 2,675,000 shares of common stock at $0.02 per share.
OID
John W. Huemoeller II, CEO of AXIM Biotechnologies, acquired a convertible note worth $250,000, convertible into common stock at $0.02 per share.